Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M A Jacobson

Showing results (121-130 of 144) with videos related to

Pageof 15
Sort By:
Molecular Immunology|September 1, 1990
Heavy and light chain contributions to antigen binding in an anti-digoxin chain recombinant antibody produced by transfection of cloned anti-digoxin antibody genesR I Near, S C Ng, M Mudgett-Hunter, et al.
Journal of Molecular and Cellular Cardiology|March 29, 2001
Targeted deletion of the A3 adenosine receptor confers resistance to myocardial ischemic injury and does not prevent early preconditioningY Guo, R Bolli, W Bao, et al.
Protein Expression and Purification|June 1, 1993
Expression, purification and characterization of multigram amounts of a recombinant hybrid HV1-HV2 hirudin variant expressed in Saccharomyces cerevisiaeE D Lehman, J G Joyce, F J Bailey, et al.
Antimicrobial Agents and Chemotherapy|May 1, 1994
Pharmacodynamic relationship of pharmacokinetic parameters of maintenance doses of foscarnet and clinical outcome of cytomegalovirus retinitisM A Jacobson, B Polsky, D Causey, et al.
Antimicrobial Agents and Chemotherapy|July 1, 1994
Phase I trial of valaciclovir, the L-valyl ester of acyclovir, in patients with advanced human immunodeficiency virus diseaseM A Jacobson, J Gallant, L H Wang, et al.
The Journal of Infectious Diseases|August 1, 1993
A dose-ranging study of daily maintenance intravenous foscarnet therapy for cytomegalovirus retinitis in AIDSM A Jacobson, D Causey, B Polsky, et al.
The American Review of Respiratory Disease|July 1, 1991
Morbidity and mortality of patients with AIDS and first-episode Pneumocystis carinii pneumonia unaffected by concomitant pulmonary cytomegalovirus infectionM A Jacobson, J Mills, J Rush, et al.
The Journal of Infectious Diseases|June 1, 1995
Pharmacokinetic, safety, and antiviral profiles of oral ganciclovir in persons infected with human immunodeficiency virus: a phase I/II study. AIDS Clinical Trials Group, and Cytomegalovirus Cooperative Study GroupS A Spector, D F Busch, S Follansbee, et al.
Clinical Pharmacology and Therapeutics|April 1, 1995
Foscarnet and ganciclovir pharmacokinetics during concomitant or alternating maintenance therapy for AIDS-related cytomegalovirus retinitisF T Aweeka, J G Gambertoglio, F Kramer, et al.
The Journal of Infectious Diseases|February 1, 1994
Primary prophylaxis with pyrimethamine for toxoplasmic encephalitis in patients with advanced human immunodeficiency virus disease: results of a randomized trial. Terry Beirn Community Programs for Clinical Research on AIDSM A Jacobson, C L Besch, C Child, et al.
Pageof 15

Showing results (121-130 of 144) with videos related to

Sort By:
Pageof 15
Molecular Immunology|September 1, 1990
Heavy and light chain contributions to antigen binding in an anti-digoxin chain recombinant antibody produced by transfection of cloned anti-digoxin antibody genesR I Near, S C Ng, M Mudgett-Hunter, et al.
Journal of Molecular and Cellular Cardiology|March 29, 2001
Targeted deletion of the A3 adenosine receptor confers resistance to myocardial ischemic injury and does not prevent early preconditioningY Guo, R Bolli, W Bao, et al.
Protein Expression and Purification|June 1, 1993
Expression, purification and characterization of multigram amounts of a recombinant hybrid HV1-HV2 hirudin variant expressed in Saccharomyces cerevisiaeE D Lehman, J G Joyce, F J Bailey, et al.
Antimicrobial Agents and Chemotherapy|May 1, 1994
Pharmacodynamic relationship of pharmacokinetic parameters of maintenance doses of foscarnet and clinical outcome of cytomegalovirus retinitisM A Jacobson, B Polsky, D Causey, et al.
Antimicrobial Agents and Chemotherapy|July 1, 1994
Phase I trial of valaciclovir, the L-valyl ester of acyclovir, in patients with advanced human immunodeficiency virus diseaseM A Jacobson, J Gallant, L H Wang, et al.
The Journal of Infectious Diseases|August 1, 1993
A dose-ranging study of daily maintenance intravenous foscarnet therapy for cytomegalovirus retinitis in AIDSM A Jacobson, D Causey, B Polsky, et al.
The American Review of Respiratory Disease|July 1, 1991
Morbidity and mortality of patients with AIDS and first-episode Pneumocystis carinii pneumonia unaffected by concomitant pulmonary cytomegalovirus infectionM A Jacobson, J Mills, J Rush, et al.
The Journal of Infectious Diseases|June 1, 1995
Pharmacokinetic, safety, and antiviral profiles of oral ganciclovir in persons infected with human immunodeficiency virus: a phase I/II study. AIDS Clinical Trials Group, and Cytomegalovirus Cooperative Study GroupS A Spector, D F Busch, S Follansbee, et al.
Clinical Pharmacology and Therapeutics|April 1, 1995
Foscarnet and ganciclovir pharmacokinetics during concomitant or alternating maintenance therapy for AIDS-related cytomegalovirus retinitisF T Aweeka, J G Gambertoglio, F Kramer, et al.
The Journal of Infectious Diseases|February 1, 1994
Primary prophylaxis with pyrimethamine for toxoplasmic encephalitis in patients with advanced human immunodeficiency virus disease: results of a randomized trial. Terry Beirn Community Programs for Clinical Research on AIDSM A Jacobson, C L Besch, C Child, et al.
Pageof 15